Role of angiotensin and oxidative stress in essential hypertension

Hypertension

Volumn 34, Issue 4 II, 1999, Pages 943-949

  Romero, J Carlos ^a,c   Reckelhoff, Jane F ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Angiotensin II; Endothelin; Hypertension, essential; Isoprostane; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN; ARACHIDONIC ACID; ENDOTHELIN; ISOPROSTANE; NITRIC OXIDE; PEROXYNITRITE; SODIUM; SUPEROXIDE; ANGIOTENSIN II; PROSTAGLANDIN F2 ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; ESSENTIAL HYPERTENSION; EXTRACELLULAR SPACE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RENOVASCULAR HYPERTENSION; SIGNAL TRANSDUCTION; SODIUM INTAKE; VASOCONSTRICTION; ANIMAL; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANGIOTENSIN II; ANIMALS; DINOPROST; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 0033209906     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.34.4.943     Document Type: Conference Paper

References (74)

1. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17: 151-183.
2. DeWardener H. The primary role of the kidney and salt intake in the aetiology of essential hypertension. Clin Sci. 1990;19:193-200.
3. Laragh JH. The meaning of plasma renin measurements: renin and sodium volume-mediated (low renin) forms of vasoconstriction in experimental and human hypertension and in the oedematous states of nephrosis and heart failure. J Hypertens. 1984;1:141-150.
4. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979;90:19-23.
5. Nelson EB, Harm SC, Goldberg M, Shahinfar S, Goldberg A, Sweet CS. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:2895-2916.
6. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA. Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
7. Sealey JE, Rubattu S. Prorenin and renin as separate mediators of tissue and circulating systems. Am J Hypertens. 1989;2:358-366.
8. Dickinson CJ, Oxon DM, Lawrence JR, Adelaide MB. A slowly developing pressor response to small concentrations of angiotensin: its bearing on the pathogenesis of chronic renal hypertension. Lancet. 1963; 1:1354-1356.
9. McCubbin JW, DeMoura RS, Page IH, Olmsted F. Arterial hypertension elicited by subpressor amounts of angiotensin. Science. 1965;149: 1394-1395.
10. Lever AF. The fast and the slowly developing pressor effect of angiotensin II. In: Ian J, Robertson S, Nicholls MG, eds. The Renin-Angiotensin System. London, UK: Gower Medical Publishing; 1993:28.1-28.9.
11. Munoz JM, Braun-Menendez E, Fasciolo JC, Leloir LJ. Hypertension: the substance causing renal hypertension. Nature. 1939;144:980.
12. Griendling KK, Alexander RW. Cellular mechanisms of angiotensin II action. In: Swales JD, ed. Textbook of Hypertension. Oxford, UK: Blackwell Scientific Publishing; 1994:244-253.
13. Ames RP, Borkowski AJ, Sicincki AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171-1186.
14. Brown AJ, Casals-Stenzel J, Gofford S, Lever AJ, Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol. 1981;241:H381-H388.
15. Haas JA, Krier JD, Bolterman RJ, Romero JC. Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension. 1999;33:1079.
16. Bean BL, Brown JJ, Casals-Stenzel J, Fraser R, Lever AF, Miller JA, Morton JJ, Petch B, Riegger AJG, Robertson JIS, Tree M. The relation of arterial pressure and plasma angiotensin II concentration: a change produced by prolonged infusion of angiotensin II in the conscious dog. Circ Res. 1979;44:452-458.
17. Majewski H, Tung L-H, Rand MJ. Adrenaline-induced hypertension. J Cardiovasc Pharmacol. 1981;3:179-185.
18. Zabludowski J, Clark S, Ball SG, Brown AJ, Inglis GC, Lever AF, Murray G. Pressor effects of brief and prolonged infusions of epinephrine in the conscious rat. Am J Physiol. 1984;246:H683-H689.
19. Gorbea-Oppliger VJ, Melaragno MG, Potter GS, Petit RL, Fink GD. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. J Pharmacol Exp Ther. 1994;271:804-810.
20. Smith JB, Smith L, Brown ER, Barnes D, Sabir MA, Davis JS, Farese RV. Angiotensin II rapidly increases phosphatidate-phosphoinositide synthesis and phosphoinositide hydrolysis and mobilizes intracellular calcium in cultured arterial muscle cells. Proc Natl Acad Sci U S A. 1984;81:7812-7816.
21. Nabika T, Velletri PA, Lovenberg W, Beaven MA. Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [Arg] vasopressin in vascular smooth muscle cells. J Biol Chem. 1985; 260:4661-4670.
22. Alexander RW, Brock TA, Gimbrone MA Jr, Rittenhouse SE. Angiotensin increases inositol trisphosphate and calcium in vascular smooth muscle. Hypertension. 1985;7:447-451.
23. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA Jr, Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem. 1986;261:5901-5906.
24. Smith JB. Angiotensin-receptor signaling in cultured vascular smooth muscle cells. Am J Physiol. 1986;250:F759-F769.
25. Rasmussen H, Barrett PQ. Calcium messenger system: an integrated view. Physiol Rev. 1984;64:938-984.
26. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol. 1996;7:2025-2043.
27. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995;268: L699-L722.
28. Chua BHL, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1993;1178:201-206.
29. Kohno M, Horio T, Ikeda M, Yokokawa K, Fukui T, Yasunari K, Kurihara N, Takeda T. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992;42:860-866.
30. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary endothelial cells. J Mol Cell Cardiol. 1990;22:839-842.
31. 2α, in the rat. J Clin Invest. 1992;90:136-141.
32. 2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993;264:C1619-C1624.
33. 2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmac. 1995;26: S51-S52.
34. Michael JR, Markewitz BA, Kohan DE. Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells. Am J Physiol. 1997;273:L768-L774.
35. Romero JC, Feldstein AE, Rodriguez-Porcel MG, Cases-Amenos A. New insights into the pathophysiology of renovascular hypertension. Mayo Clin Proc. 1997;72:251-260.
36. Shanley PF. The pathology of chronic renal ischemia. Semin Nephrol. 1996;16:21-32.
37. Kellerman PS. Cellular and metabolic consequences of chronic ischemia on kidney function. Semin Nephrol. 1996;16:33-42.
38. Hennington BS, Zhang H, Miller MT, Granger JP, Reckelhoff JF. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension. 1998;31:283-288.
39. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85: 587-590.
40. Saijonmaa O, Ristimaki A, Fyhrquist F. Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochem Biophys Res Comm. 1990;173:514-520.
41. Hirata Y, Matsuoka H, Kimura K, Sugimoto T, Hayakawa H, Suzuki E, Sugimoto T. Role of endothelium-derived relaxing factor in endothelin-induced renal vasoconstriction. J Cardiovasc Pharmacol. 1991;17:5169.
42. Lerman AJ, Sandok EK, Hildebrand FL Jr, Burnett JC Jr. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation. 1992;85:1894-1898.
43. Qui Q, Engles K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol. 1995;6: 1476-1481.
44. Richard V, Hogie M, Clozel M, Löffler B-M, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation. 1995;91:771-775.
45. Fujita K, Matsumura Y, Miyazaki Y, Takaoka M, Morimoto S. Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. Eur J Pharmacol. 1995;280:311-316.
46. Best PJM, Lerman LO, Romero JC, Holmes DR Jr, Lerman A. Chronic endothelin receptor antagonism preserves coronary nitric oxide activity in experimental hypercholesterolemia. Arterioscler Thromb Vasc Biol. In press.
47. Harris PJ, Zhou J, Mendelsohn FAO, Skinner SL. Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats. J Physiol. 1991;433:25-39.
48. Schnermann J, Lorenz JN, Briggs JP, Keiser JA. Induction of water diuresis by endothelin in rats. Am J Physiol. 1992;263:F516-F526.
49. Morrow JD, Harris TM, Roberts LJ II. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem. 1990;184:1-10.
50. Pryor WA, Stanley JP, Blair E. Autoxidation of polyunsaturated fatty acids, II: a suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipids. 1976;11: 370-379.
51. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res, 1997;36:1-21.
52. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-9387.
53. 2-isoprostanes) in carbon tetrachloride hepatotoxicity: an animal model of lipid peroxidation. J Clin Invest. 1992;90:2502-2507.
54. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. N Engl J Med. 1995; 332:1198-1203.
55. 2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A. 1992;89:10721-10725.
56. Awad JA, Roberts LJ II, Burk RF. Morrow JD. Isoprostanes - prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Gastroenterol Clin North Am. 1996;25:409-427.
57. 2α, is formed in vivo. Biochim Biophys Acta. 1994;1210:244-248.
58. Reckelhoff JF, Kanji V, Racusen LC, Schmidt AM, Van SY, Morrow J, Roberts LJ II, Salahudeen AK. Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. Am J Physiol. 1998;274:R767-R774.
59. 2α in isolated perfused rat lung. J Appl Physiol. 1993;74:460-465.
60. 2α, in rabbit lung in situ. Am J Physiol. 1992;263:H660-H663.
61. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 1992;44:155-163.
62. Balzy M, Kaminski PM, Mao K, Tan J, Wolin MS. S-nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. J Biol Chem. 1998;273:32009-32015.
63. Davidson CA, Kaminski PM, Wolin MS. NO elicits prolonged relaxation of bovine pulmonary arteries via endogenous peroxynitrite generation. Am J Physiol. 1997;273:L437-L444.
64. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res. 1997;33:422-432.
65. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol. 1996;271:H1262-H1266.
66. Benkusky NA, Lewis SJ, Kooy NW. Peroxynitrite-mediated attenuation of alpha- and beta-adrenoceptor agonist-induced vascular responses in vivo. Eur J Pharmacol. 1999;8:151-158.
67. Benkusky NA, Lewis SJ, Kooy NW. Attenuation of vascular relaxation after development of tachyphylaxis to peroxynitrite in vivo. Am J Physiol. 1998;275:H501-H507.
68. Villa LM, Salas E, Darley-Usmar VM, Radomski MW, Moncada S. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci USA. 1994;91:12383-12387.
69. Zou M, Jendral M, Ullrich V. Prostaglandin endoperoxide-dependent vasospasm in bovine coronary arteries after nitration of prostacyclin synthase. Br J Pharmacol. 1999;126:1283-1292.
70. Guyton AC, Cowley AW Jr, Coleman TG, Liard JF, McCaa RE, Manning RD Jr, Norman RA Jr, Young DB. Pretubular versus tubular mechanisms of renal hypertension. Excerpta Medica International Congress Series No. 302. 1973;15-29.
71. DeClue JW, Guyton AC, Cowley AW, Coleman TG, Norman RA, McCaa RE. Subpressor angiotensin infusions, renal sodium handling and salt-induced hypertension in the dog. Circ Res. 1978;43:503-512.
72. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D, Sterzel RB. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension. 1989;14:396-403.
73. Deng X, Welch WJ, Wilcox CS. Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension. 1996;27:1173-1179.
74. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic. Hypertension. 1998;32:59-64.